Sex development is a complex process that relies on a well-coordinated series of events at the chromosomal, gonadal, and tissue levels \[[@bib1]\]. Disruption in this process can result in disorders of sex development (DSD). DSD constitute a heterogeneous group of conditions in which development of chromosomal, gonadal, or anatomic sex is atypical \[[@bib2]\]. Clinical presentation is variable, with obvious ambiguous genitalia at birth in some cases and male or female external genitalia with discordant internal reproductive anatomy in others. Clinical recognition may be delayed until puberty or adulthood in the latter form \[[@bib1]\].

Limited data are available on the exact incidence of DSD with genital ambiguity at birth, which has been estimated to be approximately 1 in 4500 to 5500 \[[@bib3]\]. Moreover, most of the published data are coming from Western countries in which consanguinity rates are lower. A German study reported that ambiguous genitalia incidence was fourfold higher in infants of non-German origin compared with the general population \[[@bib4]\], which they attributed to an increase in autosomal recessive forms of DSD due to higher rates of consanguinity in migrant populations. Other studies support this hypothesis. The incidence of ambiguous genitalia was reported as 1 in 2500 live births in Saudi Arabia \[[@bib5]\] and 1 in 3000 live births in Egypt \[[@bib6]\], rates higher than the reported frequency in European countries. Furthermore, in those studies many cases of ambiguous genitalia lacked an accurate diagnosis.

Our primary objective was to determine the frequency of ambiguous genitalia in a population of babies born in Istanbul, Turkey.

1. Material and Methods {#s9}
=======================

We conducted this study in three tertiary care hospitals (Istanbul University, Istanbul Faculty of Medicine Hospital, Zeynep Kamil Women\'s and Children\'s Hospital, Sisli Etfal Training and Research Hospital) in Istanbul, Turkey. All 14,177 babies born in these three hospitals during an 18-month period were included in this study. All newborns were first examined at birth (within 2 days). Examinations were done in warm conditions with the child in supine position. Appearance, symmetry or asymmetry of the genitalia, size of the penis or clitoris, appearance of the labioscrotal folds, location of the urethral opening, and presence or absence and location of palpable gonads were examined, along with a detailed physical examination. Diagnostic criteria for DSD were ambiguous genitalia and/or mass at inguinal region or labium (predominantly female phenotype) and penoscrotal hypospadias, bilateral nonpalpable testes, and micropenis (predominantly male phenotype). Discordance between prenatal or postnatal karyotype and phenotype and discordance between internal and external genitalia were other criteria. Babies with bilateral nonpalpable testes were evaluated for congenital adrenal hyperplasia (CAH) and other rare disorders, but if they had normal male internal genitalia, they were not included in our ambiguous genitalia group. Data on weeks of gestation, birth weight, and birth length were available for 6201 babies. Birth weight and birth length were expressed as SD score (SDS) according to national standards for gestational age and for the same karyotype \[[@bib7]\]. Small for gestational age (SGA) was defined as birth weight less than −2 SDS for gestational age. Prematurity was defined as birth before 37 weeks of gestation. Babies suspected of having DSD were referred to the pediatric endocrinology clinics at the three hospitals.

A. Evaluation of Babies With Ambiguous Genitalia {#s10}
------------------------------------------------

A structured questionnaire was used for data collection, including history focused on the time just before and during the pregnancy, specifically referring to medications and exposure to hormonal agents. A detailed family history, including consanguinity, birth defects, atypical genital development, and unexplained infant deaths, was gathered from the parents. A comprehensive physical examination, including evaluation for dysmorphic features, was done to identify other associated anomalies. We used Quigley and Prader scales for phenotypic grading \[[@bib8], [@bib9]\]; external genital appearance of all babies with ambiguous genitalia is described in [Table 1](#tbl1){ref-type="table"}. The levels of serum electrolytes, gonadotropins, anti-Müllerian hormone, sex hormones, and their precursors were measured and karyotype analysis was done. Pelvic ultrasonography was performed to look for the presence and symmetry of Müllerian structures and the location and structural characteristics of intra-abdominal gonads. Genetic analysis of single candidate genes based on the information gathered from previous phenotypic investigations was the last step of the diagnostic process. However, some patients were lost to follow-up and some did not accept genetic testing.

###### 

Clinical and Laboratory Features of Patients With Ambiguous Genitalia

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   BW SDS   GW   Description of External Genitalia                                                                                                                             Prader/Quigley Scale                     Karyotype     Relevant Laboratory Results                                                                                                                                     Working Clinical Diagnosis   Genetic Diagnosis                                            Sex of Rearing
  --------- -------- ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------ ----------------
  1         0.1      38   Phallus dorsal 1.8 cm, ventral 1.2 cm, chordee +, scrotal hypospadias, bifid scrotum, right gonad nonpalpable, left gonad palpable 1 mL                       4                                        45,X/46, XY   Pelvic and scrotal USG: Müllerian structures+, right streak gonad, left gonad in the scrotum 12 × 8.3 mm                                                        MGD                          Nnot studied                                                 M

  2         1.5      38   Phallus dorsal 2 cm, ventral 1.5 cm, penoscrotal hypospadias, bilateral nonpalpable gonads, scrotal hyperpigmentation+                                        4[^*a*^](#tblfn1){ref-type="table-fn"}   46,XX         17OHPG: 62.5 ng/mL, ACTH: 297 pg/mL                                                                                                                             CAH                          Not studied                                                  F

  3         −1.0     33   Phallus dorsal 1.4 cm, ventral 1 cm, chordee +, scrotal hypospadias, bifid scrotum, bilateral gonads palpable 1 mL                                            4                                        46,XY         2 mo old\                                                                                                                                                       PAIS                         *AR* gene mutation +                                         M
                                                                                                                                                                                                                                               Unstimulated\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                               LH: 6.8 mIU/mL, FSH: 1.4 mIU/mL, T: 1.2 ng/mL                                                                                                                                                                                                             

  4         0.2      34   Phallus dorsal 2.3 cm, ventral 1.6 cm, chordee +, penoscrotal hypospadias, right gonad 2 mL, left gonad 1 mL palpable                                         3                                        46,XY         hCG stimulation test\                                                                                                                                           5-ARD                        Not studied                                                  M
                                                                                                                                                                                                                                               T: 4.14 ng/mL, DHT: 0.25 ng/mL, T/DHT: 16.56                                                                                                                                                                                                              

  5         −2.5     36   Phallus dorsal 1.5 cm, ventral 1 cm, chordee +, penoscrotal hypospadias, bifid scrotum, bilateral gonads palpable 0.5 ml                                      3                                        46,XY         15 d old\                                                                                                                                                       PAIS                         No mutation in *AR* or *SRD5A2* genes                        M
                                                                                                                                                                                                                                               Unstimulated\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                               T: 1.45 ng/mL, DHT: 0.39 ng/mL, T/DHT: 3.72                                                                                                                                                                                                               

  6         1.5      38   Phallus dorsal 1.7 cm, ventral 1 cm, chordee +, scrotal hypospadias, bifid asymmetric scrotum, bilateral gonads palpable right 3 mL, left 1 mL                4                                        46,XY         hCG stimulation test\                                                                                                                                           PAIS                         No mutation in *AR* or *SRD5A2* gene                         M
                                                                                                                                                                                                                                               T: 2.32 ng/mL, DHT: 0.59 ng/mL T/DHT: 3.93                                                                                                                                                                                                                

  7         −1.5     34   Phallus dorsal 2.2 cm, ventral 1.4 cm, chordee +, penoscrotal hypospadias, asymmetric scrotum, right gonad palpable 2 mL, left gonad nonpalpable hydrocele+   3                                        46,XY         hCG stimulation test\                                                                                                                                           PAIS                         No mutation in *AR* or *SRD5A2* gene                         M
                                                                                                                                                                                                                                               T: 6.86 ng/mL, DHT: 0.87 ng/mL, T/DHT: 7.89                                                                                                                                                                                                               

  8         −0.8     38   Phallus dorsal 2.5 cm, ventral 1.5 cm, chordee +, penoscrotal hypospadias, bifid scrotum, bilateral gonads palpable 2 mL                                      3                                        46,XY         1 mo old\                                                                                                                                                       5-ARD                        Not studied                                                  M
                                                                                                                                                                                                                                               Unstimulated\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                               T: 2.15 ng/mL, DHT: 0.14 ng/mL, T/DHT: 15.36                                                                                                                                                                                                              

  9         −2.2     37   Phallus dorsal 2.5 cm, ventral 1.5 cm, chordee +, penile hypospadias, bilateral gonads palpable 1 mL                                                          2                                        46,XY         1 mo old\                                                                                                                                                       PAIS                         Not studied                                                  M
                                                                                                                                                                                                                                               Unstimulated\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                               T: 2.25 ng/mL, DHT: 0.61 ng/mL, T/DHT: 3.69                                                                                                                                                                                                               

  10        0.1      38   No erectile tissue, one urogenital opening, scrotum was formed, bilateral nonpalpable gonads                                                                  4                                        46,XY         USG: No Müllerian structures, bilateral testes were in inguinal canal                                                                                           MCA                          Not studied                                                  Deceased

  11        −4.3     33   Phallus dorsal 1.2 cm, ventral 0.7 cm, chordee + penoscrotal hypospadias, bifid scrotum, bilateral nonpalpable gonads                                         3                                        46,XY         1.5 mo old\                                                                                                                                                     5-ARD                        Homozygote polymorphisms in SRD5A2, no mutation in AR gene   M
                                                                                                                                                                                                                                               Unstimulated\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                               T: 1.85 ng/mL, DHT: 0.11 ng/mL, T/DHT: 16.81                                                                                                                                                                                                              

  12        −0.9     36   Phallus dorsal 1.8 cm, ventral 1 cm, chordee +, scrotal hypospadias, bifid scrotum, bilateral gonads palpable 1 mL                                            4                                        46,XY         hCG stimulation test T: 3.58 ng/mL, DHT: 0.59 ng/mL, T/DHT: 6.06                                                                                                PAIS                         not studied                                                  M

  13        −1.5     28   Phallus dorsal 0.9 cm, ventral 0.6 cm, chordee+, penoscrotal hypospadias, bifid scrotum, bilateral nonpalpable gonads                                         3                                        46,XY         hCG stimulation test\                                                                                                                                           PAIS                         Not studied                                                  M
                                                                                                                                                                                                                                               T: 2.83 ng/mL, DHT: 0.37 ng/mL, T/DHT: 7.65                                                                                                                                                                                                               

  14        −1.3     33   Phallus dorsal 0.7 cm, ventral 0.5 cm, penoscrotal hypospadias, bifid scrotum, bilateral palpable gonads in the inguinal canal                                3                                        Not studied   Not studied                                                                                                                                                     MCA                          Not studied                                                  Deceased

  15        −1.2     38   Phallus dorsal 2.2 cm, ventral 1 cm, chordee + penoscrotal hypospadias, bilateral palpable gonads in the inguinal canal                                       3                                        46,XY         hCG stimulation test\                                                                                                                                           PAIS                         Not studied                                                  M
                                                                                                                                                                                                                                               T: 4.3 ng/mL, DHT: 0.65 ng/mL, T/DHT: 6.62                                                                                                                                                                                                                

  16        1.0      31   Phallus dorsal 1.2 cm, ventral 0.8 cm, chordee +, penoscrotal hypospadias, scrotal hypoplasia, bilateral nonpalpable gonads                                   3                                        46,XY         2 mo old\                                                                                                                                                       PAIS                         Not studied                                                  M
                                                                                                                                                                                                                                               Unstimulated\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                               T: 1.8 ng/mL, DHT: 0.33 ng/mL, T/DHT: 5.46                                                                                                                                                                                                                

  17        −0.0     37   Phallus dorsal 3.7 cm, ventral 3.7 cm, no hypospadias, bilateral nonpalpable gonads                                                                           1                                        46,XY         Pelvic USG: Uterus and bilateral fallopian tubes+, bilateral intra-abdominal gonads. Biopsy: Bilateral testicular tissue AMH \<0.1 ng/mL, inhibin B: 69 pg/mL   PMDS                         Not studied                                                  M

  18        −2.4     39   Phallus dorsal 2 cm, ventral 1.4 cm, chordee +, penoscrotal hypospadias, scrotal hypoplasia, bilateral nonpalpable gonads                                     3                                        46,XY         Pelvic USG: No Müllerian structures, bilateral abdominal gonads                                                                                                 MCA                          Not studied                                                  M
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: 5-ARD, 5 *α*-reductase deficiency; 17OHPG, 17-hydroxyprogesterone; ACTH, adrenocorticotropic hormone; AMH, anti-Müllerian hormone; AR, androgen receptor; BW, birth weight; DHT, dihydrotestosterone; F, female; GW, gestational week; hCG, human chorionic gonadotropin; M, male; MGD, mixed gonadal dysgenesis; PMDS, persistent Müllerian duct syndrome; *SRD5A2*, steroid 5 *α*-reductase 2; T, testosterone; USG, ultrasonography; UTR, untranslated region.

Prader staging.

The Istanbul University Review Board approved this study, and parents of patients with ambiguous genitalia signed informed consent forms.

B. Data Analyses {#s11}
----------------

Statistical analysis was performed by using SPSS Statistical Package, version 15 (IBM Inc., Chicago, IL). Data are presented as the mean ± SDS. Comparisons were made by using independent samples *t*-test, Mann-Whitney *U* test, or *χ*^2^ test. Statistical significance was defined as *P* ≤ 0.05.

2. Results {#s12}
==========

The study included 14,177 newborns, 18 of whom (1.3/1000) had ambiguous genitalia. One newborn was diagnosed with 46,XX CAH, one was diagnosed with 45,X/46,XY mixed gonadal dysgenesis, and 15 were diagnosed with 46,XY DSD ([Table 1](#tbl1){ref-type="table"}). Karyotype analysis was not done in one baby who had multiple congenital anomalies (MCA) and died in the neonatal period ([Table 1](#tbl1){ref-type="table"}). Of the 15 babies with 46,XY DSD, 9 were diagnosed with partial androgen insensitivity syndrome (PAIS), 3 with 5 *α*-reductase deficiency, 2 with MCA, and 1 with persistent Müllerian duct syndrome ([Table 1](#tbl1){ref-type="table"}). Among all 18 patients with DSD, only 1 had a genetically confirmed diagnosis (patient 3, with a genetic diagnosis of PAIS) ([Table 1](#tbl1){ref-type="table"}).

Two patients with MCA died in the newborn period. Sex of rearing was male in all surviving patients except one patient with CAH ([Table 1](#tbl1){ref-type="table"}). One patient with genetically confirmed PAIS had ectopic left kidney ([Table 2](#tbl2){ref-type="table"}).

###### 

Concomitant Conditions, Mothers' Disease, Medication Status, and Consanguinity in Patients With Ambiguous Genitalia

  Patient   Concomitant Conditions     Mother\'s Disease    Mothers Medication   Consanguinity
  --------- -------------------------- -------------------- -------------------- ---------------
  1         No                         Depression           No                   No
  2         No                         No                   No                   No
  3         Ectopic kidney             Preeclampsia         No                   No
  4         No                         Preeclampsia         No                   First degree
  5         No                         HT, GDM              Methyldopa           No
  6         No                         No                   No                   No
  7         No                         Preeclampsia         No                   No
  8         No                         No                   No                   Second degree
  9         No                         No                   No                   No
  10        CHD, polydactyly           No                   No                   No
  11        No                         Preeclampsia         No                   No
  12        No                         No                   No                   No
  13        No                         No                   No                   No
  14        URA, anal atresia          Insulin resistance   Metformin            No
  15        No                         No                   Levonorgestrel       No
  16        No                         No                   No                   No
  17        No                         Depression           Paroxetine           First degree
  18        Dysmorphic features, CCA   No                   No                   No

Abbreviations: CCA, corpus callosum agenesis; CHD, congenital heart disease; HT, hypertension; URA, unilateral renal agenesis.

Eight babies with DSD were born to a mother who had additional medical conditions during pregnancy, such as preeclampsia, depression, insulin resistance, and gestational diabetes mellitus (GDM) ([Table 2](#tbl2){ref-type="table"}).

Four babies with DSD were born to a mother with a history of medication use during the first trimester of pregnancy. Those medications were levonorgestrel, paroxetine, methyldopa and metformin ([Table 2](#tbl2){ref-type="table"}).

Consanguinity was found in three families ([Table 2](#tbl2){ref-type="table"}), and two families had other members with DSD (families 12 and 17).

Mean gestational age was lower in babies with DSD, and the ratio of prematurity was higher in the DSD group ([Table 3](#tbl3){ref-type="table"}). Mean birth weight SDS was lower in babies with DSD, and the SGA ratio was higher in the DSD group ([Table 3](#tbl3){ref-type="table"}). All the SGA babies had 46,XY karyotype ([Table 1](#tbl1){ref-type="table"}). Birth length SDS did not significantly differ between babies with and those without DSD ([Table 3](#tbl3){ref-type="table"}).

###### 

Comparison of Clinical Characteristics of Babies With or Without Ambiguous Genitalia

  Variable              With Ambiguous Genitalia (n = 18)   Without Ambiguous Genitalia (n = 6183)   *P* Value
  --------------------- ----------------------------------- ---------------------------------------- -----------
  Birth weight SDS      −0.85 ± 1.6                         0.18 ± 1.4                               0.009
  Birth length SDS      −0.97 ± 2.0                         −0.23 ± 1.4                              0.4
  SGA, %                22.2                                4.7                                      0.007
  Gestational age, wk   35.5 ± 3.1                          38.2 ± 2.5                               \<0.001
  Prematurity, %        44.4                                11.1                                     \<0.001

Values are means ± SDs unless otherwise stated.

We also compared the anthropometric measurements of newborn boys and girls without ambiguous genitalia. Healthy newborn boys (n = 3178) were heavier (3170 ± 650 g vs 3044 ± 604 g; *P* \< 0.001) and taller (n = 3005; 48.6 ± 3.3 cm vs 48.1 ± 3.1 cm; *P* \< 0.001) than the girls. Gestational age did not differ between sexes (38.1 ± 2.5 weeks vs 38.2 ± 2.5 weeks; *P* = 0.08).

3. Discussion {#s13}
=============

This Turkish study reports on ambiguous genitalia frequency in a large population of newborns. We found a higher rate of ambiguous genitalia than in previous studies, which were mostly from Western countries with a consanguineous marriage rate \<5% \[[@bib10]\]. However, in Turkey this rate is around 20% to 25%, causing a higher incidence of autosomal recessive diseases \[[@bib11]\]. In our study group, the consanguineous marriage rate does not seem to be very high, but in populations with a high consanguineous marriage rate, the actual relationship coefficient between the couples is much higher than the one calculated based on the information given \[[@bib12]\]. In addition, previous studies were retrospective or used registries with a low capture rate \[[@bib4]\], but ours was a prospective study. However, our study was conducted in three tertiary care hospitals with higher frequency of complicated pregnancies, which may explain higher rates of DSD with prematurity, SGA, and coexistence of maternal morbidities.

Most of our patients had 46,XY DSD; only one newborn was diagnosed with 46,XX CAH and one with 45,X/46,XY mixed gonadal dysgenesis. Unlike our results, ∼50% of all cases with DSD have been reported to be due to 46,XX DSD or sex chromosome DSD \[[@bib3], [@bib4], [@bib13]\]. The worldwide incidence of CAH has been estimated to be 1 in 14,000 to 15,000 live births \[[@bib16]\], and the frequency of testicular or mixed gonadal dysgenesis is estimated at 1:10,000 \[[@bib3]\]. However, DSD incidence has been reported to be 1 in 20,000 among patients with 46,XY karyotype \[[@bib3]\]. In our study, frequency of 46,XY DSD was 1.1/1000 among all births. One 46,XX baby with CAH and ambiguous genitalia in 14,177 babies is consistent with the literature frequency values \[[@bib16], [@bib17]\] because studies on CAH frequency were done with blood screening; however, we screened newborns with physical examination and could identify only the virilized females. With this result, we estimated 100% capture rate in our study.

Unfortunately, we had a very low rate of genetic confirmation in our study group. That made definitive diagnosis impossible in most cases. Although important advances in our knowledge have been achieved over the last decade, only a limited number of genes involved in the DSD process are available for clinical testing \[[@bib3]\]. During the study period, the standard for genetic diagnosis was sequencing a small number of known genes chosen as likely candidates based on disease phenotype, and with this method genetic etiology remained unclear in most cases \[[@bib3], [@bib18]\]. A recent position paper about molecular genetic diagnosis of DSD recommended a new parallel approach \[[@bib19]\]. In this integrative approach, clinical phenotype is considered in parallel with the biochemical and genetic data. Additionally, the authors recommended using a high-throughput sequencing panel or whole exome sequencing for the analysis of candidate genes \[[@bib19]\]. Whole genome sequencing can be used as one of the firstline tests for diagnosis in the near future, but currently there are difficulties, including long turnaround times, high costs, a lack of national health care system coverage, and difficulties in the interpretation of the results \[[@bib3]\].

Cox *et al.* \[[@bib20]\] reported that SGA was observed in 23% of 46,XY DSD cases with associated conditions. Similarly, in our study, mean birth weight SDS was lower in babies with 46,XY DSD, and the SGA ratio was 22% in the DSD group. The association between SGA and DSD has long been recognized \[[@bib21]\]. Furthermore, although the cause of birth weight difference is unknown, boys are heavier than girls at birth, and we showed the same result in our healthy cohort. It has been speculated that *in utero* androgen action may alter prenatal growth \[[@bib22]\], and some previous studies have supported this hypothesis \[[@bib23]\]; however, others reported no association between prenatal androgens and birth weight \[[@bib24], [@bib25]\]. Alternative hypotheses for the origins of low birth weight in 46,XY DSD cases include genetic factors, early placental dysfunction, and endocrine disrupters \[[@bib22], [@bib26], [@bib27]\]. Because fetal masculinization occurs between gestational weeks 8 and 14 and during the first 14 weeks of gestation placental human chorionic gonadotropin controls fetal testosterone secretion, a dysfunctional placenta may lead to growth retardation and hypospadias \[[@bib26], [@bib27]\]. Therefore, placental insufficiency can mimic PAIS, causing severe undermasculinization with normal testicular androgen production \[[@bib24]\]. We could find only one androgen receptor gene mutation among four patients who were tested; genetic analysis was not done in five patients. This is why some of our patients with a clinical diagnosis of PAIS may have ambiguous genitalia due to early placental dysfunction.

Epidemiological studies have also identified an association between hypospadias with some risk factors tied to SGA, including prematurity, preeclampsia, and placental insufficiency \[[@bib28]\]. Huisma *et al.* \[[@bib28]\] reported that a cohort of SGA boys had an increased ratio of severe to mild hypospadias. In addition, the prevalence of prematurity, maternal hypertension, and oligohydramnios was higher among those with severe vs mild hypospadias. Similarly, in our study, mean gestational age was lower and the ratio of prematurity was higher in babies with DSD. Sekaran et al. \[[@bib29]\] reported that prematurity and intrauterine growth restriction are significantly associated with proximal hypospadias and undescended testis.

In our study group there were four mothers with preeclampsia and one mother with hypertension and antihypertensive use in the first trimester. It is believed that early placental dysfunction creates immune alteration and vascular disorder and causes preeclampsia \[[@bib30]\]. In a Danish Nationwide Cohort Study, Arendt *et al.* \[[@bib31]\] reported that boys of mothers with preeclampsia had the highest occurrence of cryptorchidism and hypospadias, increasing with preeclampsia severity. They proposed that preeclampsia and genital anomalies share common etiologic factors and that placental dysfunction and androgen deficiency in early pregnancy are important in the etiology of male genital anomalies. Similarly, Caton *et al.* \[[@bib32]\] reported an association between hypertension, antihypertensive medication use, and the risk of severe hypospadias, particularly when medication use began late in pregnancy. Because genital masculinization occurs in early pregnancy, they suggested that hypertension and its morphologic/physiologic precursors play an etiologic role, perhaps via compromised uteroplacental perfusion.

One mother had GDM (patient number 5) and another one had insulin resistance and metformin use during the first trimester in our study group (patient 14). García-Patterson *et al.* \[[@bib33]\] reported that severity of GDM is a predictor of congenital malformations, with a 0.3% hypospadias rate in those patients. Metformin is an oral glucose-lowering agent that acts mainly by improving the sensitivity of peripheral tissue and the liver to insulin, thus opposing insulin resistance \[[@bib34]\]. In a meta-analysis of eight studies, Gilbert *et al.* \[[@bib35]\] concluded that first-trimester exposure to metformin is not associated with an increased risk for major malformations. More recently, Andrade \[[@bib36]\] reported that metformin exposure during the first trimester does not seem to be associated with major congenital malformations, and metformin reduces the risk for early pregnancy loss, preeclampsia, preterm delivery, and GDM in women with polycystic ovarian disease.

Two mothers had depression in our study, and one of them had also used paroxetine. Pregnancy is a period of relatively high risk for depressive episodes. Psychiatric disorders are present in 14% of pregnant women and major depression may affect nearly 5% of patients \[[@bib37]\]. Reis and Källén \[[@bib38]\] reported that the congenital malformation rate was increased with the use of tricyclic antidepressants and verified an association between use of paroxetine and hypospadias. However, it was not clear how much of this was due to medication or underlying pathology.

One mother in our study stated that she had used levonorgestrel as an emergency contraceptive. Progestogens may act as weak androgens or antiandrogens based on the structural similarity with the receptors \[[@bib34]\]. Using data from the National Birth Defects Prevention Study, Carmichael *et al.* \[[@bib39]\], reported that the rate of hypospadias was 8.4% in babies whose mothers used progestins from 4 weeks before conception to 14 weeks after and 2.4% in controls. However, that study had no information on the dose and method of administration for most women and did not specify the type of progestin and indication. De Santis *et al.* \[[@bib40]\] reported that the failure of levonorgestrel as an emergency contraceptive was not associated with an increased risk for major congenital malformations, prepartum or peripartum complications, or an adverse pregnancy outcome.

Three babies in our study had MCA and one had PAIS and ectopic kidney. Similar to our results, the frequency of concomitant conditions in patients with DSD has been reported at around 23% to 38% \[[@bib4], [@bib20], [@bib24]\]. Although DSD and renal anomalies are often encountered together in patients with gonadal dysgenesis, rare cases with androgen insensitivity syndrome and renal anomalies have been described previously \[[@bib20]\]. Human sex development is closely linked to the development of the urological system. Moreover, in mice, the kidney is one of the most androgen-sensitive organs, with a close correlation between kidney mass and androgen levels \[[@bib41]\].

Two of our patients with MCA died in the newborn period. Thyen et al. \[[@bib4]\] reported a 10% mortality rate in patients with ambiguous genitalia and all but one of those infants had complex syndromes like our cases.

The current study may be of interest because it is a Turkish study reporting ambiguous genitalia frequency in a large newborn population. Many previous studies used registries with a low capture rate, but this was a prospective study. We found a very high rate of DSD compared with the literature, and this would be an important element for comparison in future epidemiologic studies. This study has some limitations, however. It was performed in tertiary care hospitals, which would cause a selection bias because complicated pregnancies were referred to these centers. Additionally, we did not have a genetic diagnosis in most of our patients.

In conclusion, DSD frequency in this study was 1.3 in 1000 births, which was higher than previous studies. We found that mean birth weight SDS was lower and SGA ratio higher in babies with 46,XY DSD. Preeclampsia was a common concomitant condition in those pregnancies. These findings support the hypothesis that early placental dysfunction and androgen deficiency might be important in the etiology of male genital anomalies.

***Disclosure Summary:*** The authors have nothing to disclose.

CAH

:   congenital adrenal hyperplasia

DSD

:   disorders of sex development

GDM

:   gestational diabetes mellitus

MCA

:   multiple congenital anomalies

PAIS

:   partial androgen insensitivity syndrome

SDS

:   SD score

SGA

:   small for gestational age
